Commonwealth of Pennsylvania Public School Empls Retrmt SYS Lowers Holdings in Flexion Therapeutics Inc (FLXN)

Commonwealth of Pennsylvania Public School Empls Retrmt SYS reduced its holdings in shares of Flexion Therapeutics Inc (NASDAQ:FLXN) by 86.5% during the 3rd quarter, according to its most recent 13F filing with the SEC. The fund owned 13,509 shares of the specialty pharmaceutical company’s stock after selling 86,491 shares during the period. Commonwealth of Pennsylvania Public School Empls Retrmt SYS’s holdings in Flexion Therapeutics were worth $327,000 as of its most recent filing with the SEC.

Other institutional investors have also modified their holdings of the company. Fiduciary Trust Co. purchased a new stake in shares of Flexion Therapeutics in the second quarter valued at about $101,000. IFP Advisors Inc boosted its holdings in shares of Flexion Therapeutics by 24.5% in the second quarter. IFP Advisors Inc now owns 5,080 shares of the specialty pharmaceutical company’s stock valued at $103,000 after acquiring an additional 1,000 shares in the last quarter. Advisor Group Inc. boosted its holdings in shares of Flexion Therapeutics by 205.9% in the second quarter. Advisor Group Inc. now owns 5,200 shares of the specialty pharmaceutical company’s stock valued at $105,000 after acquiring an additional 3,500 shares in the last quarter. SG Americas Securities LLC purchased a new stake in shares of Flexion Therapeutics in the third quarter valued at about $135,000. Finally, State Board of Administration of Florida Retirement System purchased a new stake in shares of Flexion Therapeutics in the third quarter valued at about $235,000. 72.82% of the stock is currently owned by institutional investors.

Shares of Flexion Therapeutics Inc (FLXN) opened at $25.47 on Friday. The company has a current ratio of 12.93, a quick ratio of 12.93 and a debt-to-equity ratio of 0.87. Flexion Therapeutics Inc has a 52 week low of $16.51 and a 52 week high of $32.25.

In related news, insider Neil Bodick acquired 2,700 shares of Flexion Therapeutics stock in a transaction that occurred on Tuesday, November 21st. The stock was purchased at an average price of $24.49 per share, for a total transaction of $66,123.00. Following the completion of the purchase, the insider now directly owns 64,605 shares of the company’s stock, valued at $1,582,176.45. The purchase was disclosed in a document filed with the SEC, which is available through the SEC website. Also, insider Michael D. Clayman acquired 5,000 shares of Flexion Therapeutics stock in a transaction that occurred on Wednesday, November 8th. The stock was bought at an average price of $23.60 per share, with a total value of $118,000.00. Following the purchase, the insider now directly owns 35,395 shares of the company’s stock, valued at $835,322. The disclosure for this purchase can be found here. 15.98% of the stock is owned by company insiders.

Several analysts have recently weighed in on FLXN shares. Needham & Company LLC lifted their target price on shares of Flexion Therapeutics from $36.00 to $42.00 and gave the company a “buy” rating in a report on Monday, October 9th. Wells Fargo & Company set a $39.00 target price on shares of Flexion Therapeutics and gave the company a “buy” rating in a report on Friday, October 6th. Northland Securities reaffirmed a “buy” rating and issued a $40.00 target price on shares of Flexion Therapeutics in a report on Wednesday, October 4th. Royal Bank Of Canada set a $44.00 target price on shares of Flexion Therapeutics and gave the company a “buy” rating in a report on Monday, September 11th. Finally, Laidlaw reaffirmed a “buy” rating and issued a $38.00 target price (up previously from $35.00) on shares of Flexion Therapeutics in a report on Tuesday, October 10th. One research analyst has rated the stock with a sell rating, two have given a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the company. The company has a consensus rating of “Buy” and an average target price of $98.33.

WARNING: “Commonwealth of Pennsylvania Public School Empls Retrmt SYS Lowers Holdings in Flexion Therapeutics Inc (FLXN)” was first published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this report on another website, it was illegally copied and republished in violation of US & international copyright & trademark legislation. The correct version of this report can be accessed at https://www.dispatchtribunal.com/2017/12/10/commonwealth-of-pennsylvania-public-school-empls-retrmt-sys-lowers-holdings-in-flexion-therapeutics-inc-flxn.html.

Flexion Therapeutics Profile

Flexion Therapeutics, Inc is a United States-based specialty pharmaceutical company. The Company is focused on the development and commercialization of local therapies for the treatment of patients with musculoskeletal conditions, beginning with osteoarthritis (OA), a type of degenerative arthritis. The Company’s lead product candidate, Zilretta, is a late-stage, injectable, extended-release, intra-articular (IA) investigational steroid.

Want to see what other hedge funds are holding FLXN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Flexion Therapeutics Inc (NASDAQ:FLXN).

Institutional Ownership by Quarter for Flexion Therapeutics (NASDAQ:FLXN)

Receive News & Ratings for Flexion Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Flexion Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply